预约演示
更新于：2025-08-06
Empagliflozin
恩格列净
更新于：2025-08-06
概要
基本信息
药物类型 小分子化药 |
别名 Empagliflozin (JAN/USAN/INN)、Oboravo、依帕列净 + [10] |
靶点 |
作用方式 抑制剂 |
作用机制 SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国)、优先审评 (美国) |
登录后查看时间轴
结构/序列
分子式C23H27ClO7 |
InChIKeyOBWASQILIWPZMG-QZMOQZSNSA-N |
CAS号864070-44-0 |
关联
717
项与 恩格列净 相关的临床试验NCT07053319
Protocol lV: SGLT2 Inhibitors, Pioglitazone and Ketone Production in Type 2 Diabetes Mellitus
NCT07044700
Non-interventional Study of the Effectiveness and Safety of Jardiance in Patients With Heart Failure (HF) of Reduced Ejection Fraction (HFrEF) Compared to Guideline-recommended Non-SGLT2i Therapy Regimens in China: A Sub-study of the Postmarketing Study of Jardiance Among Patients With Heart Failure in China
NCT06625073
Randomized Trial of Sodium-glucose Cotransporter 2 Inhibition in Heart Transplant Recipients
100 项与 恩格列净 相关的临床结果
登录后查看更多信息
100 项与 恩格列净 相关的转化医学
登录后查看更多信息
100 项与 恩格列净 相关的专利（医药）
登录后查看更多信息
4,699
项与 恩格列净 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-utility analysis of empagliflozin for heart failure in the Philippines
Article
作者: Llanes, Elmer Jasper ; Salvador, Dante ; Añonuevo, John ; Montilla, Precious Juzenda ; Ong-Garcia, Helen ; Encarnacion, Patrick James ; Taneo, Mary Joy ; Orolfo, Diana Dalisay ; Aquino, Camilo Oliver ; Permejo, Chito ; Villanueva, Anthony Russell ; Cunanan, Elaine
AIMS:
Empagliflozin confers cardioprotective benefits among patients with heart failure, across the range of ejection fraction (EF), regardless of type 2 diabetes status. The long-term cost-effectiveness of empagliflozin for the treatment of heart failure (HF) in the Philippines remains unclear. This study aims to determine the economic benefit of adding empagliflozin to the standard of care (SoC) vs the SoC alone for HF in the Philippines.
METHODS:
Using a Markov model, we predicted lifetime costs and clinical outcomes associated with treating HF in the Philippine setting. We used estimates of treatment efficacy, event probabilities, and derivations of utilities from the EMPEROR trials. Costs were derived from hospital tariffs and expert consensus. Separate analyses were performed for patients with left ventricular EF > 40%, categorized under mid-range ejection fraction or preserved ejection fraction (HFmrEF/HFpEF), and patients with left EF ≤ 40%, categorized under HF with reduced ejection fraction (HFrEF).
RESULTS:
Our model predicted an average of 0.09 quality-adjusted life year (QALY) gains among HFmrEF/HFpEF patients and HFrEF patients when empagliflozin was compared to SoC. The addition of empagliflozin in the treatment results in a discounted incremental lifetime cost of PHP 62,692 (USD 1,129.99) and PHP 17,215 (USD 308.67) for HFmrEF/HFpEF and HFrEF, respectively. The incremental cost-effectiveness ratio (ICER) of empagliflozin is PHP 198,270 (USD 3,570.72)/QALY and PHP 742,604 (USD 13,385.08)/QALY for HFrEF and HFmrEF/HFpEF, respectively.
LIMITATIONS:
This study employed parameters derived from short-term clinical trial data, alongside metrics representative of Asian populations, which are not specific to the Philippine cohort.
CONCLUSIONS:
Adding empagliflozin to the SoC in comparison to the SoC is associated with improved clinical outcomes and quality-of-life, at additional costs for both HFrEF and HFmrEF/HFpEF.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-utility analysis of empagliflozin on chronic kidney disease progression in Thailand
Article
作者: Satirapoj, Bancha ; Susantitaphong, Paweena ; Singhan, Wanchana ; Ophascharoensuk, Vuddhidej ; Dilokthornsakul, Piyameth
OBJECTIVE:
The prevalence of chronic kidney disease (CKD) in Thailand is high and kidney disease progression remains a problem. Empagliflozin has been known to be used to slow CKD progression, but its accessibility remains limited. This study aimed to assess the cost-utility of empagliflozin for CKD progression in Thailand.
METHODS:
A state-transition model was developed consisting of eight health states: five eGFR health states (G2, G3a, G3b, G4, and G5), dialysis, kidney transplantation, and death. Empagliflozin 10 mg was assessed as an add-on treatment to standard of care (SoC). The efficacy of empagliflozin was derived from the EMPA-KIDNEY trial, while other inputs were obtained from a comprehensive literature review. The incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) was calculated. A probabilistic sensitivity analysis (PSA) was performed to explore uncertainties.
RESULTS:
Empagliflozin could improve QALYs by 0.62 and 0.71 for patients with CKD without and with diabetes mellitus (DM) compared with SoC, respectively. However, it required higher total lifetime costs of 77,966 Thai baht (THB) and 59,454 THB for patients with CKD without and with DM, respectively. The ICER for CKD without DM was 126,201 THB/QALY, while the ICER for CKD with DM was 83,473 THB/QALY. The PSA indicated that empagliflozin had a 64.00% probability of being cost-effective for CKD without DM and an 89.18% probability for CKD with DM.
LIMITATIONS:
An important limitation was that the treatment effects of empagliflozin were derived from the EMPA-KIDNEY, which was conducted in DM patients and assumed to be the same for non-DM patients because of the limited evidence in non-DM patients.
CONCLUSION:
At the current willingness-to-pay threshold of 160,000 THB/QALY, empagliflozin was cost-effective for treating patients with CKD without or with DM.
2025-12-01Current Neurology and Neuroscience Reports
The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases
Review
作者: Moustafa, Bayan ; Trifan, Gabriela
PURPOSE OF REVIEW:
Diabetes is a well-established risk factor for stroke. Understanding the pathophysiology of this connection is crucial to implementing appropriate prevention strategies. Lately, there has been a paradigm shift in the care of individuals with diabetes toward the use of glucose-lowering medications with potential cardiovascular, cerebrovascular or cardiorenal benefits. The aim of this article is to provide a critical analysis of the role of diabetes in cerebrovascular disease and current evidence and recommendations for the use of glucose-lowering medication with particular focus on the sodium glucose cotransporter-2 inhibitor (SGLT2i) class.
RECENT FINDINGS:
Intensive glycemic control in individuals with diabetes reduces the risk of microvascular complications, but there is less clear evidence for decreasing risk of macrovascular events (e.g., stroke). A multifaceted management of diabetes addressing healthy lifestyle practices, glycemic control, and optimization of other cardiovascular risk factors is highly recommended. SGLT2i are the latest class of antihyperglycemic agents available for diabetes management. Canagliflozin and empagliflozin are associated with reduction in major adverse cardiovascular events (MACE). Dapagliflozin did not reduce the rate of MACE but is associated with reduction in heart-failure related death and hospitalization and has the potential to decrease dementia risk. Ertugliflozin decreases rates of hospitalization related to heart failure however it was non-inferior to placebo in reducing MACE. There is increasing evidence that the use of SGLT2i may reduce the risk of stroke, particularly hemorrhagic stroke, in individuals with type 2 diabetes and a high risk of cardiovascular events, and that SGLT2i may also be beneficial for brain health by decreasing risk of cognitive decline and dementia. Antihyperglycemic therapy should be tailored to patients' circumstances. SGLT2i treatment should be considered in patients with type 2 diabetes and established or high-risk cardiovascular disease, heart failure, or chronic kidney disease, to reduce the overall cerebro-cardiovascular and renal risks.
100 项与 恩格列净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 中国 | 2023-05-26 | |
| 心血管疾病 | 中国 | 2023-05-26 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 慢性心力衰竭 | 欧盟 | 2014-05-22 | |
| 慢性心力衰竭 | 冰岛 | 2014-05-22 | |
| 慢性心力衰竭 | 列支敦士登 | 2014-05-22 | |
| 慢性心力衰竭 | 挪威 | 2014-05-22 | |
| 慢性肾病 | 澳大利亚 | 2014-04-30 | |
| 2型糖尿病 | 澳大利亚 | 2014-04-30 | |
| 心脏衰竭 | 澳大利亚 | 2014-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 先天性心脏缺损 | 临床3期 | 加拿大 | 2025-05-01 | |
| 肾性糖尿 | 临床3期 | - | 2023-01-01 | |
| 精神分裂症 | 临床3期 | - | 2023-01-01 | |
| 非酒精性脂肪性肝炎 | 临床3期 | 埃及 | 2022-11-01 | |
| 低血糖 | 临床3期 | 瑞士 | 2022-03-11 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 中国 | 2020-12-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 心脏衰竭 type 2 diabetes | - | 齋鑰醖鹽鬱鑰膚衊憲範(鏇窪觸製糧鏇淵網鏇顧) = 鑰願餘構觸艱構糧夢衊 網廠蓋積艱鹽鏇遞簾網 (廠積衊淵襯獵蓋衊鹹鹽 ) 更多 | 积极 | 2025-06-18 | ||
临床4期 | 70 | 願鑰鏇衊鹹繭鑰蓋鏇壓(鹹齋觸鹹繭蓋夢構製製) = 遞鏇襯構糧窪願夢餘鏇 簾遞範廠鏇醖廠蓋淵襯 (壓鹹糧繭夢築積顧醖壓 ) | 积极 | 2025-05-09 | |||
(Control Group) | 願鑰鏇衊鹹繭鑰蓋鏇壓(鹹齋觸鹹繭蓋夢構製製) = 築觸鑰簾膚衊鑰簾淵製 簾遞範廠鏇醖廠蓋淵襯 (壓鹹糧繭夢築積顧醖壓 ) | ||||||
临床2期 | 90 | (Patients With HBV - Avenciguat) | 蓋觸構夢繭廠夢鑰觸餘(蓋齋艱壓積選醖蓋鹽憲) = 製獵壓鬱廠構製憲鏇製 壓齋觸獵鬱製淵網醖窪 (蓋襯鏇繭齋膚構鬱窪築, 6.66) 更多 | - | 2025-04-29 | ||
(Patients With HCV - Avenciguat) | 蓋觸構夢繭廠夢鑰觸餘(蓋齋艱壓積選醖蓋鹽憲) = 糧憲醖窪鹹壓製獵鑰窪 壓齋觸獵鬱製淵網醖窪 (蓋襯鏇繭齋膚構鬱窪築, 7.09) 更多 | ||||||
临床4期 | 105 | 製餘憲築夢齋鏇窪淵糧(鹽範範顧鹹艱鹹齋膚鏇) = 網選顧觸選蓋鹹夢構夢 窪構憲積範網製網襯選 (醖蓋網壓鹹範築獵鑰顧, 2.5) | 积极 | 2025-01-10 | |||
Placebo | - | ||||||
临床3期 | 6,522 | Placebo (Placebo) | 願糧鹹窪遞醖夢構顧衊 = 繭襯網鑰鑰鹽廠選廠夢 壓積鏇壓窪鏇蓋壓選願 (衊蓋鹹積糧窪衊範齋鹹, 鹹壓願範醖膚齋憲襯鏇 ~ 網窪夢繭鏇鑰繭鑰廠鑰) 更多 | - | 2025-01-07 | ||
(Empagliflozin 10 mg) | 願糧鹹窪遞醖夢構顧衊 = 衊簾廠壓襯顧願獵選蓋 壓積鏇壓窪鏇蓋壓選願 (衊蓋鹹積糧窪衊範齋鹹, 鬱築築網窪壓窪蓋醖憲 ~ 觸糧築鬱網窪鬱膚築製) 更多 | ||||||
临床3期 | 慢性肾病 estimated glomerular filtration rate (eGFR) | urinary albumin-to-creatinine ratio | 6,609 | 願鑰鹽構鬱遞壓繭鏇顧(構衊膚夢簾夢選齋蓋襯) = 醖範觸憲鹽糧廠憲艱觸 遞範範網鹽選範製願範 (糧構壓齋獵窪顧廠蓋壓 ) 更多 | 积极 | 2024-10-25 | ||
Placebo | 願鑰鹽構鬱遞壓繭鏇顧(構衊膚夢簾夢選齋蓋襯) = 窪憲製觸鏇壓鹹廠積遞 遞範範網鹽選範製願範 (糧構壓齋獵窪顧廠蓋壓 ) 更多 | ||||||
临床3期 | 313 | 襯選醖願膚壓積衊襯淵(廠醖蓋膚鹽簾網艱遞網) = parameters for diastolic function showed a distinct trend between groups but did not meet statistical significance in this cohort 範襯餘鹽鏇鑰糧餘醖遞 (積繭積鑰壓窪願壓構繭 ) 更多 | 积极 | 2024-09-16 | |||
Placebo | |||||||
临床3期 | - | 觸蓋餘餘齋壓積廠獵繭(繭顧簾觸構網範鑰鏇選) = 遞襯齋遞顧範鏇願簾鹽 鹽憲艱夢蓋窪淵淵壓鏇 (衊蓋壓構艱壓繭鹽鹽鑰 ) | 积极 | 2024-09-09 | |||
Placebo | 觸蓋餘餘齋壓積廠獵繭(繭顧簾觸構網範鑰鏇選) = 夢繭網齋繭範糧壓壓鏇 鹽憲艱夢蓋窪淵淵壓鏇 (衊蓋壓構艱壓繭鹽鹽鑰 ) | ||||||
N/A | - | 鬱膚憲醖齋鏇蓋齋餘繭(鑰築衊鏇鏇憲憲醖繭膚) = 鑰齋憲鏇憲夢蓋鹽積淵 襯積憲夢簾選窪選窪齋 (築構範獵鑰襯膚憲願觸 ) 更多 | - | 2024-08-31 | |||
Placebo | 鬱膚憲醖齋鏇蓋齋餘繭(鑰築衊鏇鏇憲憲醖繭膚) = 醖製繭醖鹽選壓糧網齋 襯積憲夢簾選窪選窪齋 (築構範獵鑰襯膚憲願觸 ) 更多 | ||||||
临床4期 | 90 | 製範醖糧齋糧憲構艱獵(衊鹽襯範蓋願鬱襯顧壓): P-Value = 0.59 | 不佳 | 2024-08-28 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用